AbbVie Inc. Reports Strong Q3 2026 Results and Raises Full‑Year Guidance
AbbVie Inc. (NYSE: ABBV) released its third‑quarter 2026 earnings on Friday, October 26, 2026. The biopharmaceutical company posted a diluted earnings per share (EPS) of $2.37 on a GAAP basis and $3.82 in adjusted terms, both figures representing increases of more than 100 % over the same period last year. Net revenues reached $17.404 billion, up 10.3 % year‑over‑year and in line with the consensus estimate of $17.32 billion.
Drivers of the Upswing
The results were largely driven by continued double‑digit year‑over‑year growth for AbbVie’s immunology products Skyrizi and Rinvoq. Both drugs posted expansions of over 22 % in Q3 2026, offsetting the 31 % decline in sales of the once‑top‑selling biologic Humira. The immunology portfolio, which includes treatments for psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis, has become the company’s primary growth engine.
Updated Guidance
In the earnings call, AbbVie’s management lifted its adjusted earnings‑per‑share forecast for the full fiscal year 2026 to a range of $13.95–$13.99, up from the previous $13.84–$13.88. The company also raised its revenue outlook to $67.8 billion. The stronger outlook reflects the momentum in the immunology segment and a lower effective tax rate, which has helped improve profitability.
Dividend Enhancement
AbbVie announced an increase in its quarterly dividend of 5.2 %, reflecting confidence in its cash‑flow generation and a commitment to returning value to shareholders. The dividend hike accompanies the earnings guidance upgrade, underscoring the company’s positive outlook.
Market Reaction
Following the announcement, AbbVie shares opened slightly lower in pre‑market trading, despite the favorable earnings beat. Analysts noted that the stock’s valuation remains high, with a price‑to‑earnings ratio of 80.89, and that investors may weigh the company’s heavy reliance on a limited set of high‑growth immunology products.
Financial Snapshot
| Metric | Q3 2026 | YoY % |
|---|---|---|
| Net revenue | $17.404 bn | +10.3 % |
| GAAP diluted EPS | $2.37 | +100 % |
| Adjusted diluted EPS | $3.82 | +100 % |
| Full‑year 2026 adjusted EPS guidance | $13.95–$13.99 | — |
| Full‑year 2026 revenue guidance | $67.8 bn | — |
AbbVie’s market capitalization stands at approximately $505 bn, and its stock closed at $290.79 on October 28, 2026, near the 52‑week high of $292.67.
Outlook
The company’s strategy now focuses on sustaining growth in the immunology space while managing the decline of Humira. AbbVie’s leadership indicated that future pipeline development and potential new indications for existing drugs will be critical to maintaining momentum. The updated guidance and dividend increase suggest a positive trajectory, though investors remain cautious about the high valuation multiples and the concentration risk inherent in a few key products.
